glp 1 and perimenopause GLP-1 Microdosing for Perimenopause: Benefits & Risks Weight Loss During Perimenopause: Rooted

There is no absolute contraindication listed in FDA labeling for GLP-1 receptor agonists or tirzepatide specifically related to existing gallstones

doi: 10.1517/14656566.7.15.2095 [DOI] [PubMed] [Google Scholar] 143

Management primarily emphasizes lifestyle modifications, particularly weight reduction, as approximately 80% of PCOS patients are overweight or obese [5]

doi: 10.2196/39741

Members lose 29% more weight with Med+ At 12 months, Med+ members prescribed a GLP-1 medication who engaged regularly with the GLP-1 Success Program lost 29.1% more body weight , on average, than those who did not engage in behavioral support*